Richter Group

Formycon is a global, independent biosimilars specialist focused on developing and commercializing biosimilar therapeutics. Its pipeline centers on a ranibizumab biosimilar for Lucentis, with additional candidates targeting indications such as Stelara and Eylea at varying stages of development. The company also operates as a contract development and manufacturing organization, offering end-to-end analytical development, pre-formulation, formulation development for systemic and local delivery, stability testing, and manufacturing process development for clinical and marketed products. This integrated platform supports both internal programs and external clients, providing comprehensive development services from protein characterization through quality control.

Quris Technologies is an artificial intelligence innovator focused on transforming the pharmaceutical industry. The company has developed a bio clinical-prediction platform that utilizes AI to enhance the safety and efficacy of new drugs. This fully automated and self-trained platform predicts clinical outcomes more quickly and cost-effectively, while significantly reducing the need for animal testing through the use of patients-on-a-chip technology. By enabling pharmaceutical companies to mitigate the risks and expenses associated with failed clinical trials, Quris aims to improve the drug development process and promote more reliable testing methods.

Finox AG is a Swiss company founded in 2007, specializing in the development of fertility drugs and innovative delivery devices. The company's flagship product is BEMFOLA, a recombinant-human follicle-stimulating hormone designed for fertility treatment, which is accompanied by the BEMFOLA injector pen, a single-use device that enables patients to self-administer their medication conveniently. With a commitment to providing high-quality and cost-effective fertility solutions, Finox AG markets its products both domestically and internationally. The company has established a presence in multiple locations across Europe, Australia, and the United States. Finox AG operates as a subsidiary of Techpharma Management AG, and as of 2016, it is under the ownership of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

Mediplus is a marketing company based in Curaçao, which covers through its subsidiaries a number of countries in the Latin American region, namely: Ecuador, Peru, Chile and Bolivia.

Next Pharma serves the needs of large private and public hospitals, retail chains as well as government agencies in Brazil and its strength is the detection of cutting edge products for specific niches in the pharmaceutical market place and subsequently their successful registration by the local government authorities.

PregLem is a Swiss-based specialty biopharmaceutical company focused on developing and commercializing innovative drugs specifically for women's reproductive medicine. The company is dedicated to addressing unmet medical needs in this field, aiming to enhance healthcare options and improve outcomes for women. Through its specialized approach, PregLem seeks to advance the understanding and treatment of conditions related to female reproductive health, positioning itself as a key player in the biopharmaceutical industry.

Granata Bio is a biotechnology company established in 2018 that specializes in identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility-related treatments and leverages its expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in fertility treatment. Recently, the company announced a partnership with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to improving fertility care.